Giardiasis, Drug Resistance, and New Target Discovery

Infectious Disorders - Drug Targets

Volumn 10, Issue 4, 2010, Pages 295-302

  Tian, Hai Feng ^a,b   Chen, Bing ^a,b   Wen, Jian Fan ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Drug resistance; Giardia lamblia; Giardiasis; Target; Vaccine

Indexed keywords

4 NITROIMIDAZOLE; ALBENDAZOLE; ARGININE DEIMINASE; CYSTEINE; FURAZOLIDONE; GARDIA VACCINE; GIARDIAVAX; LIPID; MEBENDAZOLE; MEPACRINE; METRONIDAZOLE; NIMORAZOLE; NITAZOXANIDE; ORNIDAZOLE; PAROMOMYCIN; PROTEIN; PURINE; PYRIMIDINE; SECNIDAZOLE; TINIDAZOLE; UNCLASSIFIED DRUG; VACCINE;

ANAEROBIC GLYCOLYSIS; DNA SYNTHESIS; DRUG RESEARCH; DRUG TARGETING; ENERGY METABOLISM; GIARDIASIS; HUMAN; LIPID METABOLISM; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN SYNTHESIS; PURINE METABOLISM; PYRIMIDINE METABOLISM; REVIEW;

EID: 77958548154     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152610791591629     Document Type: Review

References (118)

1. Volotão, A. C.; Costa-Macedo, L. M.; Haddad, F. S. M.; Brandão, A.; Peralta, J. M.; Fernandes, O. Genotyping of Giardia duodenalisfrom human and animal samples from Brazil using beta-giardingene: a phylogenetic analysis. Acta Trop., 2007, 102(1), 10-19.
2. Feng, Y.; Ortega, Y.; Cama, V.; Terrel, J.; Xiao, L. High intragenotypicdiversity of Giardia duodenalis in dairy cattle on three farms. Parasitol. Res., 2008, 103(1), 87-92.
3. Homan, W. L.; Mank, T. G. Human giardiasis: genotype linkeddifferences in clinical symptomatology. Int. J. Parasitol., 2001, 31(8), 822-826.
4. Read, C.; Walters, J.; Robertson, I. D.; Thompson, R. C. A. Correlationbetween genotype of Giardia duodenalis and diarrhoea. Int. J. Parasitol., 2002, 32(2), 229-231.
5. Sahagun, J.; Clavel, A.; Goni, P.; Seral, C.; Llorente, M. T.; Castillo, F. J.; Capilla, S.; Arias, A.; Gomez-Lus, R. Correlation betweenthe presence of symptoms and the Giardia duodenalis genotype. Eur. J. Clin. Microbiol. Infect. Dis., 2008, 27(1), 81-83.
6. Farthing, M. J. The molecular pathogenesis of giardiasis. J. Pediatr. Gastroenterol. Nutr., 1997, 24(1), 79-88.
7. Müller, N.; von Allmen, N. Recent insights into the mucosal reactionsassociated with Giardia lamblia infections. Int. J. Parasitol., 2005, 35(13), 1339-1347.
8. Roxström-Lindquist, K.; Palm, D.; Reiner, D.; Ringqvist, E.; Svärd, S. G. Giardia immunity--an update. Trends Parasitol., 2006, 22(1), 26-31.
9. Hanevik, K.; Hausken, T.; Morken, M. H.; Strand, E. A.; Mørch, K.; Coll, P.; Helgeland, L.; Langeland, N. Persisting symptoms andduodenal inflammation related to Giardia duodenalis infection. J. Infect., 2007, 55(6), 524-530.
10. Mørch, K.; Hanevik, K.; Rortveit, G.; Wensaas, K. A.; Langeland, N. High rate of fatigue and abdominal symptoms 2 years after anoutbreak of giardiasis. Trans. R. Soc. Trop. Med. Hyg., 2009, 103(5), 530-532.
11. Angarano, G.; Maggi, P.; Bari, M. A. D.; Larocca, A. M.; Congedo, P.; Bari, C. D.; Brandonisio, O.; Chiodo, F. Giardiasis in HIV: apossible role in patients with severe immune deficiency. Eur. J. Epidemiol., 1997, 13(4), 485-487.
12. Feitosa, G.; Bandeira, A. C.; Sampaio, D. P.; Badaró, R.; Brites, C. High prevalence of giardiasis and stronglyloidiasis among HIVinfectedpatients in Bahia, Brazil. Braz. J. Infect. Dis., 2001, 5(6), 339-344.
13. Gonçalves, A. C. M.; Gabbay, Y. B.; Mascarenhas, J. D; Yassaka, M. B.; Moran, L. C.; Fraga, V. D.; Castro, E.; Franco, C.; Machado, R. L. D.; Rossit, A. R. B. Calicivirus and Giardia lamblia are associatedwith diarrhea in human immunodeficiency virus-seropositivepatients from southeast Brazil. Am. J. Trop. Med. Hyg., 2009, 81(3), 463-466.
14. Giardiasis. www.giardiasis.org/ (Accessed Jan 5, 2010).
15. Savioli, L.; Smith, H.; Thompson, A. Giardia and Cryptosporidiumjoin the 'Neglected Diseases Initiative'. Trends Parasitol., 2006, 22(5), 203-208.
16. Thompson, J.; Yang, R.; Power, M.; Hufschmid, J.; Beveridge, I.; Reid, S.; Ng, J.; Armson, A.; Ryan, U. Identification of zoonoticGiardia genotypes in marsupials in Australia. Exp. Parasitol., 2008, 120(1), 88-93.
17. Sprong, H.; Cacciò, S. M.; van der Giessen, J. W. B.; on behalf of theZOOPNET network and partners. Identification of zoonotic genotypesof Giardia duodenalis. PLoS Negl. Trop. Dis., 2009, 3(12), e558.
18. Upcroft, P.; Upcroft, J. A. Drug targets and mechanisms of resistancein the anaerobic protozoa. Clin. Microbiol. Rev., 2001, 14(1), 150-164.
19. Escobedo, A. A.; Cimerman, S. Giardiasis: a pharmacotherapyreview. Expert Opin. Pharmacother., 2007, 8(12), 1885-1902.
20. Gardner, T. B.; Hill, D. R. Treatment of giardiasis. Clin. Microbiol. Rev., 2001, 14(1), 114-128.
21. Raether, W.; Hänel, H. Nitroheterocyclic drugs with broad spectrumactivity. Parasitol. Res., 2003, 90(Supp1), S19-S39.
22. Orozco, E.; Marchat, L. A.; Gomez, C.; Lopez-Camarillo, C.; Perez, D. G. Drug Resistance Mechanisms In: Entamoeba histolytica,Giardia lamblia. Trichomonas vaginalis. and Opportunistic AnaerobicProtozoa; D. L. Mayers, Ed.; Humana Press, 2009; Chapter39, p. 549-559.
23. Kiser, J. D.; Paulson, C. P.; Brown, C. Clinical inquiries. What's themost effective treatment for giardiasis? J. Fam. Pract., 2008, 57(4), 270-2.
24. Adagu, I. S.; Nolder, D.; Warhurst, D. C.; Rossignol, J. F. In vitroactivity of nitazoxanide and related compounds against isolates ofGiardia intestinalis. Entamoeba histolytica and Trichomonas vaginalis. J. Antimicrob. Chemother., 2002, 49(1), 103-111.
25. Abboud, P.; Lemée V.; Gargala, G.; Brasseur, P.; Ballet, J. J.; Borsa-Lebas, F.; Caron, F.; Favennec, L. Successful treatment ofmetronidazole- and albendazole-resistant giardiasis with nitazoxanidein a patient with acquired immunodeficiency syndrome. Clin. Infect. Dis., 2001, 32(12), 1792-1794.
26. Brown, D. M.; Upcroft, J. A.; Upcroft, P. A H2O-producing NADHoxidase from the protozoan parasite Giardia duodenalis. Eur. J. Biochem., 1996, 241(1), 155-161.
27. Upcroft, J. A.; Upcroft, P. Drug susceptibility testing of anaerobicprotozoa. Antimicrob. Agents Chemother., 2001, 45(6), 1810-1814.
28. Harder, A.; Greif, G.; Haberkorn, A. Chemotherapeutic approachesto protozoa: Giardia, Trichomonas and Entamoeba -- current levelof knowledge and outlook. Parasitol. Res., 2001, 87, 785-786.
29. Upcroft, J. A.; Campbell, R. W.; Upcroft, P. Quinacrine-resistantGiardia duodenalis. Parasitology, 1996, 112(Pt 3), 309-313.
30. Thompson, R. C. A.; Reynoldson, J. A.; Mendis, A. H. W. Giardiaand giardiasis. Adv. Parasitol., 1993, 32, 71-160.
31. Namgung, R.; Ryu, J. S.; Kee, K.; Soh, C. The effect of metronidazoleand quinacrine on the morphology and excystation of Giardialamblia. Yonsei. Rep. Trop. Med., 1985, 16, 28644.
32. Katiyar, S.; Vivesvara, G.; Edlind, T. Comparisons of the ribosomalRNA from amitochondrial protozoa: implications for processing, mRNA binding and paromomycin susceptibility. Gene, 1995, 152, 27-33.
33. Elmendorf, H. G.; Dawson, S. C.; McCaffery, J. M. The cytoskeletonof Giardia lamblia. Int. J. Parasitol., 2003, 33(1), 3-28.
34. Crossley, R.; Marshall, J.; Clark, J. T; Holberton, D. V. Immunocytochemicaldifferentiation of microtubules in the cytoskeleton ofGiardia lamblia using monoclonal antibodies to alpha-tubulin andpolyclonal antibodies to associated low molecular weight proteins. J. Cell. Sci., 1986, 80, 233-52.
35. Oxberry, M. E.; Thompson, R. C.; Reynoldson, J. A. Evaluation ofthe effects of albendazole and metronidazole on the ultrastructureof Giardia duodenalis. Trichomonas vaginalis and Spironucleusmuris using transmission electron microscopy. Int. J. Parasitol., 1994, 24(5), 695-703.
36. Venkatesan, P. Albendazole. J. Antimicrob, Chemother., 1998, 41(2), 145-7.
37. de Silva, N.; Guyatt, H.; Bundy, D. Anthelmintics. A comparativereview of their clinical pharmacology. Drugs, 1997, 53(5), 769-88.
38. Olson, M. E.; Morck, D. W.; Ceri, H. The efficacy of a Giardialamblia vaccine in kittens. Can. J. Vet. Res., 1996, 60(4), 249-256.
39. Olson, M. E.; Ceri, H.; Morck, D. W. Giardia vaccination. Parasitol. Today, 2000, 16(5), 213-217.
40. Jiménez, J. C.; Fontaine, J.; Grzych, J. M.; Dei-Cas, E.; Capron, M. Systemic and mucosal responses to oral administration of excretoryand secretory antigens from Giardia intestinalis. Clin. Diagn. Lab. Immunol., 2004, 11(1), 152-160.
41. Stäger, S.; Gottstein, B.; Müller, N. Systemic and local antibodyresponse in mice induced by a recombinant peptide fragment fromGiardia lamblia variant surface protein (VSP) H7 produced by aSalmonella typhimurium vaccine strain. Int. J. Parasitol., 1997, 27(8), 965-971.
42. Larocque, R.; Nakagaki, K.; Lee, P.; Abdul-Wahid, A.; Faubert, G. M. Oral immunization of BALB/c mice with Giardia duodenalisrecombinant cyst wall protein inhibits shedding of cysts. Infect. Immun., 2003, 71(10), 5662-5669.
43. Lee, P.; Faubert, G. M. Oral immunization of BALB/c mice byintragastric delivery of Streptococcus gordonii-expressing Giardiacyst wall protein 2 decreases cyst shedding in challenged mice. FEMS Microbiol. Lett., 2006, 265(2), 225-236.
44. Lee, P.; Abdul-Wahid, A.; Faubert, G. M. Comparison of the localimmune response against Giardia lamblia cyst wall protein 2 inducedby recombinant Lactococcus lactis and Streptococcusgordonii. Microbes Infect., 2009, 11(1), 20-28.
45. Ali, V.; Nozaki, T. Current therapeutics, their problems, and sulfurcontaining-amino-acid metabolism as a novel target against infectionsby "amitochondriate" protozoan parasites. Clin. Microbiol. Rev., 2007, 20(1), 164-187.
46. Upcroft, J.; Mitchell, R.; Chen, N.; Upcroft, P. Albendazole resistancein Giardia is correlated with cytoskeletal changes but notwith a mutation at amino acid 200 in beta-tubulin. Microb. DrugResist., 1996, 2(3), 303-308.
47. Upcroft, J. A.; Campbell, R. W.; Benakli, K.; Upcroft, P.; Vanelle, P. Efficacy of new 5-nitroimidazoles against metronidazolesusceptibleand -resistant Giardia. Trichomonas, and Entamoebaspp. Antimicrob. Agents Chemother., 1999, 43(1), 73-76.
48. Lindquist, H. D. Induction of albendazole resistance in Giardialamblia. Microb. Drug Resist., 1996, 2(4), 433-434.
49. Sterk, M.; Müller, J.; Hemphill, A.; Müller, N. Characterization ofa Giardia lamblia WB C6 clone resistant to the isoflavone formononetin. Microbiology, 2007, 153(Pt 12), 4150-4158.
50. Argüello-García, R.; Cruz-Soto, M.; Romero-Montoya, L.; Ortega-Pierres, G. In vitro resistance to 5-nitroimidazoles and benzimidazolesin Giardia duodenalis: variability and variation in gene expression. Infect. Genet. Evol., 2009, 9(6), 1057-1064.
51. Upcroft, J. A.; Dunn, L. A.; Wright, J. M.; Benakli, K.; Upcroft, P.; Vanelle, P. 5-Nitroimidazole drugs effective against metronidazoleresistantTrichomonas vaginalis and Giardia duodenalis. Antimicrob. Agents Chemother., 2006, 50(1), 344-347.
52. Müller, J.; Sterk, M.; Hemphill, A.; Müller, N. Characterization ofGiardia lamblia WB C6 clones resistant to nitazoxanide and tometronidazole. J. Antimicrob. Chemother., 2007, 60(2), 280-287.
53. Townson, S. M.; Upcroft, J. A.; Upcroft, P. Characterisation andpurification of pyruvate:ferredoxin oxidoreductase from Giardiaduodenalis. Mol. Biochem. Parasitol., 1996, 79(2), 183-193.
54. Dan, M.; Wang, A. L.; Wang, C. C. Inhibition of pyruvate-ferredoxinoxidoreductase gene expression in Giardia lamblia by a virus-mediated hammerhead ribozyme. Mol. Microbiol., 2000, 36(2), 447-456.
55. Liu, S. M.; Brown, D. M.; O'Donoghue, P.; Upcroft, P.; Upcroft, J. A. Ferredoxin involvement in metronidazole resistance of Giardiaduodenalis. Mol. Biochem. Parasitol., 2000, 108(1), 137-140.
56. Müller, J.; Ley, S.; Felger, I.; Hemphill, A.; Müller, N. Identificationof differentially expressed genes in a Giardia lamblia WB C6clone resistant to nitazoxanide and metronidazole. J. Antimicrob. Chemother., 2008, 62(1), 72-82.
57. Pal, D.; Banerjee, S.; Cui, J.; Schwartz, A.; Ghosh, S. K.; Samuelson, J. Giardia. Entamoeba, and Trichomonas enzymes activatemetronidazole (nitroreductases) and inactivate metronidazole (nitroimidazolereductases). Antimicrob. Agents Chemother., 2009, 53(2), 458-464.
58. MacDonald, L. M.; Armson, A.; Thompson, A. R. C.; Reynoldson, J. A. Characterisation of benzimidazole binding with recombinanttubulin from Giardia duodenalis. Encephalitozoon intestinalis, andCryptosporidium parvum. Mol. Biochem. Parasitol., 2004, 138(1), 89-96.
59. Jiménez-Cardoso, E.; Eligio-García, L.; Cortés-Campos, A.; Flores-Luna, A.; Valencia-Mayoral, P.; Lozada-Chávez, I. Changes inbeta-giardin sequence of Giardia intestinalis sensitive and resistantto albendazole strains. Parasitol. Res., 2009, 105(1), 25-33.
60. Zaat, J. O.; Mank, T. G.; Assendelft, W. J. A systematic review onthe treatment of giardiasis. Trop. Med. Int. Health, 1997, 2(1), 63-82.
61. Galkin, A.; Kulakova, L.; Melamud, E.; Li, L.; Wu, C.; Mariano, P.; Dunaway-Mariano, D.; Nash, T. E.; Herzberg, O. Characterization, kinetics, and crystal structures of fructose-1, 6-bisphosphatealdolase from the human parasite, Giardia lamblia. J. Biol. Chem., 2007, 282(7), 4859-4867.
62. Enriquez-Flores, S.; Rodriguez-Romero, A.; Hernandez-Alcantara, G.; la Mora-De la Mora, I. D.; Gutierrez-Castrellon, P.; Carvajal, K.; Lopez-Velazquez, G.; Reyes-Vivas, H. Species-specific inhibitionof Giardia lamblia triosephosphate isomerase by localized perturbationof the homodimer. Mol. Biochem. Parasitol., 2008, 157(2), 179-186.
63. Feng, X. M.; Cao, L. J.; Adam, R. D.; Zhang, X. C.; Lu, S. Q. Thecatalyzing role of PPDK in Giardia lamblia. Biochem. Biophys. Res. Commun., 2008, 367(2), 394-398.
64. Townson, S. M.; Boreham, P. F.; Upcroft, P.; Upcroft, J. A. Resistanceto the nitroheterocyclic drugs. Acta. Trop., 1994, 56(2-3), 173-194.
65. Horner, D. S.; Hirt, R. P.; Embley, T. M. A single eubacterial originof eukaryotic pyruvate: ferredoxin oxidoreductase genes: implicationsfor the evolution of anaerobic eukaryotes. Mol. Biol. Evol., 1999, 16(9), 1280-1291.
66. Hoffman, P. S.; Sisson, G.; Croxen, M. A.; Welch, K.; Harman, W. D.; Cremades, N.; Morash, M. G. Antiparasitic drug nitazoxanideinhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacterjejuni. Antimicrob. Agents Chemother., 2007, 51(3), 868-876.
67. Dan, M.; Wang, C. C. Role of alcohol dehydrogenase E (ADHE) inthe energy metabolism of Giardia lamblia. Mol. Biochem. Parasitol., 2000, 109(1), 25-36.
68. Adam, R. D. Biology of Giardia lamblia. Clin. Microbiol. Rev., 2001, 14(3), 447-475.
69. Li, Z.; Kulakova, L.; Li, L.; Galkin, A.; Zhao, Z.; Nash, T. E.; Mariano, P. S.; Herzberg, O.; Dunaway-Mariano, D. Mechanisms ofcatalysis and inhibition operative in the arginine deiminase fromthe human pathogen Giardia lamblia. Bioorg. Chem., 2009, 37(5), 149-161.
70. Palm, J. E. D.; Weiland, M. E. L.; Griffiths, W. J.; Ljungström, I.; Svärd, S. G. Identification of immunoreactive proteins during acutehuman giardiasis. J. Infect. Dis., 2003, 187(12), 1849-1859.
71. Ringqvist, E.; Palm, J. E. D.; Skarin, H.; Hehl, A. B.; Weiland, M.; Davids, B. J.; Reiner, D. S.; Griffiths, W. J.; Eckmann, L.; Gillin, F. D.; Svärd, S. G. Release of metabolic enzymes by Giardia in responseto interaction with intestinal epithelial cells. Mol. Biochem. Parasitol., 2008, 159(2), 85-91.
72. Touz, M. C.; Rópolo, A. S.; Rivero, M. R.; Vranych, C. V.; Conrad, J. T.; Svard, S. G.; Nash, T. E. Arginine deiminase has multiple regulatoryroles in the biology of Giardia lamblia. J. Cell Sci., 2008, 121(Pt 17), 2930-2938.
73. Galkin, A.; Kulakova, L.; Sarikaya, E.; Lim, K.; Howard, A.; Herzberg, O. Structural insight into arginine degradation by argininedeiminase, an antibacterial and parasite drug target. J. Biol. Chem., 2004, 279(14), 14001-8.
74. Adam, R. D.; Aggarwal, A.; Lal, A. A.; de La Cruz, V. F.; McCutchan, T.; Nash, T. E. Antigenic variation of a cysteine-richprotein in Giardia lamblia. J. Exp. Med., 1988, 167(1), 109-118.
75. Wang, C. C.; Aldritt, S. Purine salvage networks in Giardia lamblia. J. Exp. Med., 1983, 158(5), 1703-1712.
76. Munagala, N.; Wang, C. C. The pivotal role of guanine phosphoribosyltransferasein purine salvage by Giardia lamblia. Mol. Microbiol., 2002, 44(4), 1073-1079.
77. Aronov, A. M.; Munagala, N. R.; Kuntz, I. D.; Wang, C. C. Virtualscreening of combinatorial libraries across a gene family: in searchof inhibitors of Giardia lamblia guanine phosphoribosyltransferase. Antimicrob. Agents. Chemother., 2001, 45(9), 2571-2576.
78. Shi, W.; Sarver, A. E.; Wang, C. C.; Tanaka, K. S. E.; Almo, S. C.; Schramm, V. L. Closed site complexes of adenine phosphoribosyltransferasefrom Giardia lamblia reveal a mechanism of ribosylmigration. J. Biol. Chem., 2002, 277(42), 39981-39988.
79. Sarver, A. E.; Wang, C. C. The adenine phosphoribosyltransferasefrom Giardia lamblia has a unique reaction mechanism and unusualsubstrate binding properties. J. Biol. Chem., 2002, 277(42), 39973-39980.
80. Jarroll, E. L.; Muller, P. J.; Meyer, E. A.; Morse, S. A. Lipid andcarbohydrate metabolism of Giardia lamblia. Mol. Biochem. Parasitol., 1981, 2(3-4), 187-196.
81. Ellis, J. E.; Wyder, M. A.; Jarroll, E. L.; Kaneshiro, E. S. Changes inlipid composition during in vitro encystation and fatty acid desaturaseactivity of Giardia lamblia. Mol. Biochem. Parasitol., 1996, 81(1), 13-25.
82. Das, S.; Stevens, T.; Castillo, C.; Villasenõr, A.; Arredondo, H.; Reddy, K. Lipid metabolism in mucous-dwelling amitochondriateprotozoa. Int. J. Parasitol., 2002, 32(6), 655-675.
83. Chapoy, J. R. Identification and characterization of phospholipidmetabolic enzymes in Giardia lamblia. PhD Thesis, The Universityof Texas At El Paso: El Paso, 2005.
84. Lykidis, A. Comparative genomics and evolution of eukaryoticphospholipid biosynthesis. Prog. Lipid. Res., 2007, 46(3-4), 171-199.
85. Tian, H. F. Identification of an incomplete glycerophopholipidbiosynthesis pathway in Giardia lamblia and the evolution of glycerophospholipidbiosynthesis pathway in eukaryotes. PhD Thesis, Kunming Institute of Zoology, CAS: Kunming, August 2008.
86. Yichoy, M.; Nakayasu, E. S.; Shpak, M.; Aguilar, C.; Aley, S. B.; Almeida, I. C.; Das, S. Lipidomic analysis reveals that phosphatidylglyceroland phosphatidylethanolamine are newly generatedphospholipids in an early-divergent protozoan, Giardia lamblia. Mol. Biochem. Parasitol., 2009, 165(1), 67-78.
87. Hernandez, Y.; Castillo, C.; Roychowdhury, S.; Hehl, A.; Aley, S. B.; Das, S. Clathrin-dependent pathways and the cytoskeletonnetwork are involved in ceramide endocytosis by a parasitic protozoan,Giardia lamblia. Int. J. Parasitol., 2007, 37(1), 21-32.
88. Hernandez, Y.; Shpak, M.; Duarte, T. T.; Mendez, T. L.; Maldonado, R. A.; Roychowdhury, S.; Rodrigues, M. L.; Das, S. Novelrole of sphingolipid synthesis genes in regulating giardial encystation. Infect. Immun., 2008, 76(7), 2939-2949.
89. Sonda, S.; Stefanic, S.; Hehl, A. B. A sphingolipid inhibitor inducesa cytokinesis arrest and blocks stage differentiation in Giardialamblia. Antimicrob. Agents Chemother., 2008, 52(2), 563-569.
90. Hernandez, P. C.; Wasserman, M. Do genes from the cholesterolsynthesis pathway exist and express in Giardia intestinalis. Parasitol. Res., 2006, 98(3), 194-199.
91. Maia, C.; Attias, M.; Urbina, J.; Gilbert, I.; Magaraci, F.; de Souza, W. Azasterols impair Giardia lamblia proliferation and inducesencystation. Biochem. Biophys. Res. Commun., 2007, 363(2), 310-316.
92. Sebti, S. M.; Der, C. J. Opinion: Searching for the elusive targets offarnesyltransferase inhibitors. Nat. Rev. Cancer, 2003, 3(12), 945-951.
93. Sebti, S. M. Blocked pathways: FTIs shut down oncogene signals. Oncologist, 2003, 8(Suppl 3), 30-38.
94. Luján, H. D.; Mowatt, M. R.; Chen, G. Z.; Nash, T. E. Isoprenylationof proteins in the protozoan Giardia lamblia. Mol. Biochem. Parasitol., 1995, 72(1-2), 121-127.
95. Eastman, R. T.; Buckner, F. S.; Yokoyama, K.; Gelb, M. H.; Voorhis, W. C. V. Thematic review series: lipid posttranslationalmodifications. Fighting parasitic disease by blocking protein farnesylation. J. Lipid. Res., 2006, 47(2), 233-240.
96. Hausen, M. A.; de Oliveira, R. P.; Gadelha, A. P. R.; Campanati, L.; de Carvalho, J. J.; de Carvalho, L.; Barbosa, H. S. Giardia lamblia: areport of drug effects under cell differentiation. Parasitol. Res., 2009, 105(3), 789-796.
97. DuBois, K. N.; Abodeely, M.; Sakanari, J.; Craik, C. S.; Lee, M.; McKerrow, J. H.; Sajid, M. Identification of the major cysteine proteaseof Giardia and its role in encystation. J. Biol. Chem., 2008, 283(26), 18024-18031.
98. Touz, M. C.; Nores, M. J.; Slavin, I.; Carmona, C.; Conrad, J. T.; Mowatt, M. R.; Nash, T. E.; Coronel, C. E.; Luján, H. D. The activityof a developmentally regulated cysteine proteinase is required forcyst wall formation in the primitive eukaryote Giardia lamblia. J. Biol. Chem., 2002, 277(10), 8474-8481.
99. Touz, M. C.; Nores, M. J.; Slavin, I.; Piacenza, L.; Acosta, D.; Carmona, C.; Luján, H. D. Membrane-associated dipeptidyl peptidaseIV is involved in encystation-specific gene expression duringGiardia differentiation. Biochem. J., 2002, 364(Pt 3), 703-710.
100. Jarroll, E. L.; Sener, K. Potential drug targets in cyst-wall biosynthesisby intestinal protozoa. Drug Resist. Updat., 2003, 6(5), 239-246.
101. Karabay, O.; Tamer, A.; Gunduz, H.; Kayas, D.; Arinc, H.; Celebi, H. Albendazole versus metronidazole treatment of adult giardiasis:An open randomized clinical study. World J. Gastroenterol., 2004, 10(8), 1215-1217.
102. Suk, D. H.; Bonnac, L.; Dykstra, C. C.; Pankiewicz, K. W.; Patterson, S. E. Rational design and synthesis of novel nucleotide anti-Giardia agents. Bioorg. Med. Chem. Lett., 2007, 17(7), 2064-7.
103. Chaudhuri, P. P.; Das, D.; Sarkar, S.; Munoz, M. L.; Das, P. Biochemicaland immunological characterization of soluble antigens ofGiardia lamblia. Parasitol. Res., 1997, 83(6), 604-610.
104. Palm, D.; Weiland, M.; McArthur, A. G.; Winiecka-Krusnell, J.; Cipriano, M. J.; Birkeland, S. R.; Pacocha, S. E.; Davids, B.; Gillin, F.; Linder, E.; Svärd, S. Developmental changes in the adhesivedisk during Giardia differentiation. Mol. Biochem. Parasitol., 2005, 141(2), 199-207.
105. Davids, B. J.; Reiner, D. S.; Birkeland, S. R.; Preheim, S. P.; Cipriano, M. J.; McArthur, A. G.; Gillin, F. D. A new family of giardialcysteine-rich non-VSP protein genes and a novel cyst protein. PLoSOne, 2006, 1, e44.
106. Téllez, A.; Palm, D.; Weiland, M.; Alemán, J.; Winiecka-Krusnell, J.; Linder, E.; Svärd, S. Secretory antibodies against Giardia intestinalisin lactating Nicaraguan women. Parasite Immunol., 2005, 27(5), 163-169.
107. Davids, B. J.; Palm, J. E. D.; Housley, M. P.; Smith, J. R.; Andersen, Y. S.; Martin, M. G.; Hendrickson, B. A.; Johansen, F. E.; Svärd, S. G.; Gillin, F. D.; Eckmann, L. Polymeric immunoglobulin receptorin intestinal immune defense against the lumen-dwelling protozoanparasite Giardia. J. Immunol., 2006, 177(9), 6281-6290.
108. Uehlinger, F. D.; O'Handley, R. M.; Greenwood, S. J.; Guselle, N. J.; Gabor, L. J.; Van Velsen. C. M.; Steuart, R. F.; Barkema, H. W. Efficacyof vaccination in preventing giardiasis in calves. Vet. Parasitol., 2007, 146(1-2), 182-8.
109. Olsen, M. E.; Ceri, H.; Morck, D. W. Giardia vaccine. U. S. Patent 5,512,288, Apr 30, 1996.
110. Abdul-Wahid, A.; Faubert, G. Mucosal delivery of a transmissionblockingDNA vaccine encoding Giardia lamblia CWP2 by Salmonellatyphimurium bactofection vehicle. Vaccine, 2007, 25(50), 8372-83.
111. Stober, C. B.; Lange, U. G.; Roberts, M. T.; Gilmartin, B.; Francis, R.; Almeida, R.; Peacock, C. S.; McCann, S.; Blackwell, J. M. Fromgenome to vaccines for leishmaniasis: screening 100 novel vaccinecandidates against murine Leishmania major infection. Vaccine, 2006, 24(14), 2602-16.
112. Birkholtz, L.; van Brummelen, A. C.; Clark, K.; Niemand, J.; Maréchal, E.; Llinás, M.; Louw, A. I. Exploring functional genomics fordrug target and therapeutics discovery in Plasmodia. Acta. Trop., 2008, 105(2), 113-23.
113. Steuart, R. F. Proteomic analysis of Giardia: Studies from the preandpost-genomic era. Exp. Parasitol., 2009, 124(1), 26-30.
114. Liu, C.; Li, J.; Zhang, X.; Liu, Q.; Liu, H.; Gong, P.; Zhang, G.; Yao, L.; Zhang, X. Stable expression of green fluorescent proteinmediated by GCV in Giardia canis. Parasitol. Int., 2008, 57(3), 320-324.
115. Carpenter, M. L.; Cande, W. Z. Using morpholinos for gene knockdownin Giardia intestinalis. Eukaryot. Cell, 2009, 8(6), 916-919.
116. Singer, S. M.; Yee, J.; Nash, T. E. Episomal and integrated maintenanceof foreign DNA in Giardia lamblia. Mol. Biochem. Parasitol., 1998, 92(1), 59-69.
117. Hehl, A. B.; Marti, M.; Köhlerm P. Stage-specific expression andtargeting of cyst wall protein-green fluorescent protein chimeras inGiardia. Mol. Biol. Cell, 2000, 11(5), 1789-800.
118. Su, L. H.; Lee, G. A.; Huang, Y. C.; Chen, Y. H.; Sun, C. H. Neomycinand puromycin affect gene expression in Giardia lamblia stabletransfection. Mol. Biochem. Parasitol., 2007, 156(2), 124-135.